BioSpace News Archive

C2N Diagnostics, which recently became the first to offer a widely accessible blood test to help physicians with Alzheimer’s disease diagnosis, continues to reach important roll-out milestones.

Sharps Compliance Corp. announced that David P. Tusa, President and Chief Executive Officer, will participate in a fireside chat and conduct one-on-one meetings throughout the day at Gabelli & Company’s 7th Annual Waste & Environmental Services Symposium, to be held virtually on Thursday March 18, 2021.

The iRemedy Healthcare Companies, Inc. (“iRemedy” or “the Company”), pioneer of the iRemedy™ medical supply marketplace, today announced that the Company has arranged for the procurement of an additional 500 million low-dead space syringes and needles in association with iRemedy’s “Project Vaccinate” initiative, created to support global demand for FDA-approved injection devices required for administration of COVID-19 vaccinations.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been invited to present at the H.C. Wainwright Global Life Sciences Conference, a virtual event being held Tuesday, March 9th, and Wednesday, March 10th, 2021.

Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today that Michael Poirier, President, Chief Executive Officer and Chairman of Qualigen, will present at the Oppenheimer 31st Annual Healthcare Conference being held March 16-18 2021.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its Skyline Medical Division is renewing developing a new Generation 3 STREAMWAY ® System for direct-to-drain fluid waste management.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for UX053, an investigational mRNA therapy being evaluated for the treatment of Glycogen Storage Disease Type III (GSDIII).

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on disruptive, target-directed Natural Killer (NK) cell engager immunotherapy technologies (TriKE™) for cancer, announces preclinical results for its ROR1 TriKE™ product candidate as a prospective therapy for the treatment of prostate cancer.

MemVerge®, the pioneers of Big Memory software and Analytical BioSciences Ltd. (ABio), a leader in single cell genomics, today announced the companies have accelerated the time-to-results for single-cell RNA sequencing (scRNA-seq) analysis by using Big Memory technology

ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the first cohorts of their South Africa and U.S. COVID-19 vaccine trials have received their initial doses of the company’s T-cell-based COVID-19 vaccine candidate, hAd5.